Heart failure hospitalization following surgical or transcatheter aortic valve implantation in low-risk aortic stenosis.
Aortic stenosis cardiomyopathy
Aortic valve stenosis
Heart failure
Mortality
Prostheses and implants
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
18 Jun 2024
18 Jun 2024
Historique:
revised:
08
05
2024
received:
13
04
2024
accepted:
10
05
2024
medline:
19
6
2024
pubmed:
19
6
2024
entrez:
19
6
2024
Statut:
aheadofprint
Résumé
In low-risk patients with severe aortic stenosis (AS), sutureless surgical aortic valve replacement (SU-SAVR) may be an alternative to transcatheter aortic valve implantation (TAVI). The risk of heart failure hospitalization (HFH) after aortic valve replacement (AVR) in this population is incompletely characterized. This study aims to investigate the incidence, predictors, and outcomes of HFH in patients undergoing SU-SAVR versus TAVI. Patients referred for AVR between 2013 and 2020 at two centres were consecutively included. The decision for SU-SAVR or TAVI was determined by a multidisciplinary Heart Team. Cox regression and competing risk analysis were conducted to assess adverse events. Of 594 patients (mean age 77.5 ± 6.4, 59.8% male), 424 underwent SU-SAVR, while 170 underwent TAVI. Following a mean follow-up of 34.1 ± 23.1 months, HFH occurred in 112 (27.8%) SU-SAVR patients and in 8 (4.8%) TAVI patients (P < 0.001). The SU-SAVR cohort exhibited higher all-cause mortality (138 [32.5%] patients compared with 30 [17.6%] in the TAVI cohort [P < 0.001]). These differences remained significant after sensitivity analyses with 1:1 propensity score matching for baseline variables. SU-SAVR with HFH was associated with increased all-cause mortality (61.6% vs. 23.1%, P < 0.001). Independent associates of HFH in SU-SAVR patients included diabetes, atrial fibrillation, chronic obstructive pulmonary disease, lower glomerular filtration rate and lower left ventricular ejection fraction. SU-SAVR patients with HFH had a 12-month LVEF of 59.4 ± 12.7. In low-risk AS, SU-SAVR is associated with a higher risk of HFH and all-cause mortality compared to TAVI. In patients with severe AS candidate to SU-SAVR or TAVI, TAVI may be the preferred intervention.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O'Hair D, et al. Transcatheter aortic‐valve replacement with a self‐expanding valve in low‐risk patients. N Engl J Med 2019;380:1706‐1715. doi:10.1056/NEJMoa1816885
Thyregod HGH, Steinbrüchel DA, Ihlemann N, Nissen H, Kjeldsen BJ, Petursson P, et al. Transcatheter versus surgical aortic valve replacement in patients with severe aortic valve stenosis. J Am Coll Cardiol 2015;65:2184‐2194. doi:10.1016/j.jacc.2015.03.014
Leon MB, Mack MJ, Hahn RT, Thourani VH, Makkar R, Kodali SK, et al. Outcomes 2 years after transcatheter aortic valve replacement in patients at low surgical risk. J Am Coll Cardiol 2021;77:1149‐1161. doi:10.1016/j.jacc.2020.12.052
Baron SJ, Magnuson EA, Lu M, Wang K, Chinnakondepalli K, Mack M, et al. Health status after transcatheter versus surgical aortic valve replacement in low‐risk patients with aortic stenosis. J Am Coll Cardiol 2019;74:2833‐2842. doi:10.1016/j.jacc.2019.09.007
Kodali SK, Williams MR, Smith CR, Svensson LG, Webb JG, Makkar RR, et al. Two‐year outcomes after transcatheter or surgical aortic‐valve replacement. N Engl J Med 2012;366:1686‐1695. doi:10.1056/NEJMoa1200384
Adams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, et al. Transcatheter aortic‐valve replacement with a self‐expanding prosthesis. N Engl J Med 2014;370:1790‐1798. doi:10.1056/NEJMoa1400590
Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, et al. Transcatheter or surgical aortic‐valve replacement in intermediate‐risk patients. N Engl J Med 2016;374:1609‐1620. doi:10.1056/NEJMoa1514616
Thourani VH, Kodali S, Makkar RR, Herrmann HC, Williams M, Babaliaros V, et al. Transcatheter aortic valve replacement versus surgical valve replacement in intermediate‐risk patients: a propensity score analysis. Lancet 2016;387:2218‐2225. doi:10.1016/S0140‐6736(16)30073‐3
Siontis GCM, Praz F, Pilgrim T, Mavridis D, Verma S, Salanti G, et al. Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of severe aortic stenosis: a meta‐analysis of randomized trials. Eur Heart J 2016;37:3503‐3512.
Meco M, Montisci A, Miceli A, Panisi P, Donatelli F, Cirri S, et al. Sutureless perceval aortic valve versus conventional stented bioprostheses: meta‐analysis of postoperative and midterm results in isolated aortic valve replacement. J Am Heart Assoc 2018;7:e006091. doi:10.1161/JAHA.117.006091
Fischlein T, Caporali E, Asch FM, Vogt F, Pollari F, Folliguet T, et al. Hemodynamic performance of sutureless vs. conventional bioprostheses for aortic valve replacement: the 1‐year core‐lab results of the randomized PERSIST‐AVR trial. Front Cardiovasc Med 2022;9:844876.
Jolliffe J, Moten S, Tripathy A, Skillington P, Tatoulis J, Muneretto C, et al. Perceval valve intermediate outcomes: a systematic review and meta‐analysis at 5‐year follow‐up. J Cardiothorac Surg 2023;18:129.
Santarpino G, Pfeiffer S, Jessl J, Dell'Aquila AM, Pollari F, Pauschinger M, et al. Sutureless replacement versus transcatheter valve implantation in aortic valve stenosis: a propensity‐matched analysis of 2 strategies in high‐risk patients. J Thorac Cardiovasc Surg 2014;147:561‐567. doi:10.1016/j.jtcvs.2013.10.025
Santarpino G, Pfeiffer S, Jessl J, Dell'Aquila A, Vogt F, von Wardenburg C, et al. Clinical outcome and cost analysis of sutureless versus transcatheter aortic valve implantation with propensity score matching analysis. Am J Cardiol 2015;116:1737‐1743. doi:10.1016/j.amjcard.2015.08.043
Kamperidis V, van Rosendael PJ, de Weger A, Katsanos S, Regeer M, van der Kley F, et al. Surgical sutureless and transcatheter aortic valves: hemodynamic performance and clinical outcomes in propensity score‐matched high‐risk populations with severe aortic stenosis. JACC Cardiovasc Interv 2015;8:670‐677. doi:10.1016/j.jcin.2014.10.029
Repossini A, Di Bacco L, Passaretti B, Grubitzsch H, Schäfer C, Claus B, et al. Early hemodynamics and clinical outcomes of isolated aortic valve replacement with stentless or transcatheter valve in intermediate‐risk patients. J Thorac Cardiovasc Surg 2017;153:549‐558.e3. doi:10.1016/j.jtcvs.2016.10.086
Vilalta V, Alperi A, Cediel G, Mohammadi S, Fernández‐Nofrerias E, Kalvrouziotis D, et al. Midterm outcomes following sutureless and transcatheter aortic valve replacement in low‐risk patients with aortic stenosis. Circ Cardiovasc Interv 2021;14:e011120. doi:10.1161/CIRCINTERVENTIONS.121.011120
Généreux P, Piazza N, Alu MC, Nazif T, Hahn RT, Pibarot P, et al. Valve academic research consortium 3: updated endpoint definitions for aortic valve clinical research. J Am Coll Cardiol 2021;77:2717‐2746. doi:10.1016/j.jacc.2021.02.038
Muneretto C, Alfieri O, Cesana BM, Bisleri G, De Bonis M, Di Bartolomeo R, et al. A comparison of conventional surgery, transcatheter aortic valve replacement, and sutureless valves in “real‐world” patients with aortic stenosis and intermediate‐ to high risk profile. J Thorac Cardiovasc Surg 2015;150:1570‐1577. doi:10.1016/j.jtcvs.2015.08.052
Shinn SH, Altarabsheh SE, Deo SV, Sabik JH, Markowitz AH, Park SJ. A systemic review and meta‐analysis of sutureless aortic valve replacement versus transcatheter aortic valve implantation. Ann Thorac Surg 2018;106:924‐929. doi:10.1016/j.athoracsur.2018.03.059
Muneretto C, Solinas M, Folliguet T, Di Bartolomeo R, Repossini A, Laborde F, et al. Sutureless versus transcatheter aortic valves in elderly patients with aortic stenosis at intermediate risk: a multi‐institutional study. J Thorac Cardiovasc Surg 2022;163:925‐935. doi:10.1016/j.jtcvs.2020.04.179
Lindman BR, Goldstein JS, Nassif ME, Zajarias A, Novak E, Tibrewala A, et al. Systemic inflammatory response syndrome after transcatheter or surgical aortic valve replacement. Heart 2015;101:537‐545. doi:10.1136/heartjnl‐2014‐307057
Kimura N, Nomura Y, Aomatsu A, Matsuda A, Imamura Y, Taniguchi Y, et al. Effect of transcatheter aortic valve implantation on the immune response associated with surgical aortic valve replacement. Am J Cardiol 2020;128:35‐44. doi:10.1016/j.amjcard.2020.04.037
Guerrero‐Orriach JL, Carmona‐Luque MD, Gonzalez‐Alvarez L. Heart failure after cardiac surgery: the role of halogenated agents, myocardial conditioning and oxidative stress. Int J Mol Sci 2022;23:1360. doi:10.3390/ijms23031360
Abdel‐Wahab M, Fujita B, Frerker C, Bauer T, Beckmann A, Bekeredjian R, et al. Transcatheter versus rapid‐deployment aortic valve replacement: a propensity‐matched analysis from the german aortic valve registry. JACC Cardiovasc Interv 2020;13:2642‐2654. doi:10.1016/j.jcin.2020.09.018
Khoury H, Ragalie W, Sanaiha Y, Boutros H, Rudasill S, Shemin RJ, et al. Readmission after surgical aortic valve replacement in the United States. Ann Thorac Surg 2020;110:849‐855. doi:10.1016/j.athoracsur.2019.11.058
Trooboff SW, Magnus PC, Ross CS, Chaisson K, Kramer RS, Helm RE, et al. A multi‐center analysis of readmission after cardiac surgery: experience of the northern New England cardiovascular disease study group. J Card Surg 2019;34:655‐662. doi:10.1111/jocs.14086
Maniar HS, Bell JM, Moon MR, Meyers BF, Marsala J, Lawton JS, et al. Prospective evaluation of patients readmitted after cardiac surgery: analysis of outcomes and identification of risk factors. J Thorac Cardiovasc Surg 2014;147:1013‐1020. doi:10.1016/j.jtcvs.2013.10.066
Mujtaba SS, Ledingham S, Shah AR, Clark S, Pillay T, Schueler S. Early clinical results of perceval sutureless aortic valve in 139 patients: Freeman experience. Braz J Cardiovasc Surg 2018;33:8‐14. doi:10.21470/1678‐9741‐2017‐0087
Auensen A, Hussain AI, Falk RS, Walle‐Hansen MM, Bye J, Pettersen KI, et al. Associations of brain‐natriuretic peptide, high‐sensitive troponin T, and high‐sensitive C‐reactive protein with outcomes in severe aortic stenosis. PLoS ONE 2017;12:e0179304. doi:10.1371/journal.pone.0179304
Durand E, Doutriaux M, Bettinger N, Tron C, Fauvel C, Bauer F, et al. Incidence, prognostic impact, and predictive factors of readmission for heart failure after transcatheter aortic valve replacement. JACC Cardiovasc Interv 2017;10:2426‐2436. doi:10.1016/j.jcin.2017.09.010
Auffret V, Bakhti A, Leurent G, Bedossa M, Tomasi J, Belhaj Soulami R, et al. Determinants and impact of heart failure readmission following transcatheter aortic valve replacement. Circ Cardiovasc Interv 2020;13:e008959. doi:10.1161/CIRCINTERVENTIONS.120.008959
Aziminia N, Nitsche C, Mravljak R, Bennett J, Thornton GD, Treibel TA. Heart failure and excess mortality after aortic valve replacement in aortic stenosis. Expert Rev Cardiovasc Ther 2023;21:193‐210. doi:10.1080/14779072.2023.2186853
Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021;385:1451‐1461. doi:10.1056/NEJMoa2107038